CD19 and acute lymphoblastic leukemia: CD19-targeted chimeric antigen receptor (CAR) T-cell immunotherapy has demonstrated remarkable efficacy in managing relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) [1, 2].